Sánchez, AndrésAlape-Girón, AlbertoMoreira-Soto, AndrésArguedas, MauricioBrenes, HebleenBuján, WillemCorrales-Aguilar, EugeniaDíaz, CeciliaEcheverri, AnnFlores-Díaz, MariettaGómez, AarónHernández, AndrésHerrera, MaríaLeón, GuillermoMacaya, RománMolina-Mora, José ArturoMora, JavierNarayanan, AarthiSanabria, AlfredoSánchez, LauraSegura, ÁlvaroSegura, EduardoSolano, DanielaSoto, ClaudioStynoski, Jennifer LVargas, MariángelaVillalta, MaurenDrexler, Jan FelixGutiérrez, José María2025-07-092025-07-092021-09doi: 10.3389/fmed.2021.743325http://hdl.handle.net/20.500.11764/4907ARTICULOThe emergence and dissemination of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic triggered a global public health crisis. Although several SARS-CoV-2 vaccines have been developed, demand far exceeds supply, access to them is inequitable, and thus, populations in low- and middle-income countries are unlikely to be protected soon (1). Furthermore, there are no specific therapies available, which is a challenge for COVID-19 patient care (2). Thus, the appearance of SARS-CoV-2 variants and reports of reinfections associated with immune escape (3, 4) highlight the urgent need for effective and broad coverage COVID-19 therapeuticsenCOVID-19INMUNOTERAPIAArticle